Showing 6441-6450 of 8891 results for "".
- Revance Therapeutics Announces Pricing of Initial Public Offeringhttps://practicaldermatology.com/news/20140207-revance_therapeutics_announces_pricing_of_initial_public_offering/2459346/Revance Therapeutics, Inc., a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, announced the pricing of its initial public offering of 6,000,000 shares of its common stock at a public offering price of $16.00 per share, befo
- Valeant Pharmaceuticals Announces FDA Approval of Retin-A Micro Microsphere 0.08%https://practicaldermatology.com/news/20140131-valeant_pharmaceuticals_announces_fda_approval_of_retin-a_micro_microsphere_008/2459353/The FDA approved Valeant Pharmaceuticals' Supplemental New Drug Application (sNDA) for Retin-A Micro (tretinoin) Gel microsphere 0.08% for the topical treatment of acne vulgaris. "We are very pleased that the FDA ha
- AAD Responds to New York Timeshttps://practicaldermatology.com/news/20140127-aad_sumbits_letter_to_the_editor_to_new_york_times/2459358/In response to The New York Times article “Patients' Costs Skyrocket; Specialists' Incomes Soar” (“Paying Till It Hurts” series, Jan. 19, 2014), the American Academy of De
- DERM: The Dermatology Essential Resource Meeting Announcedhttps://practicaldermatology.com/news/20140122-derm_the_dermatology_essential_resource_meeting_announced/2459364/DERM 2014: The Dermatology Essential Resource Meeting will be held July 24-27 at the Encore in Las Vegas. This new, accredited conference focuses exclusively on clinically relevant and practical educational needs of NPs and PAs in dermatology, according t
- Anti-Aging Technology Using the “Science of Heat” to be Presented at AACShttps://practicaldermatology.com/news/20140117-anti-aging_technology_using_the_science_of_heat_to_be_presented_at_aacs/2459368/An anti-aging technology that uses the “science of heat” will be presented tomorrow at the American Academy of Cosmetic Surgery (AACS) 30th Annual Scientific Meeting in Fort Lauderdale, FL. ThermiRF is a minimally invasive method of tightening sagging skin and reducing the appearance of fine lines a
- Injectable Methotrexate Product Now Availablehttps://practicaldermatology.com/news/20140117-injectable_methotrexate_product_now_available/2459369/For patients who do not tolerate oral methotrexate for psoriasis, a new recently approved injectable methotrexate product is now available from Antares Pharma. Approved in October 2013 for the subcutaneous methotrexate product for once weekly self-administration, Otrexup is indicated for use in adul
- Caliber Imaging & Diagnostics Receives $1.4 Million Order for VivaScope® Systems From European Distributor MAVIG GmbHhttps://practicaldermatology.com/news/20140114-caliber_imaging__diagnostics_receives_14_million_order_for_vivascope_systems_from_european_distributor_mavig_gmbh/2459373/Caliber Imaging & Diagnostics (OTCQB:LCDX), formerly Lucid, Inc., announces receipt of $1.4 million in orders for VivaScope® systems from its European distributor MAVIG GmbH. These units are scheduled to be shipped in the first half of 2014. MAVIG has been Caliber's exclusive distributor in Europe f
- FDA Approves Combination Use of GSK's Mekinist® (trametinib) and Tafinlar® (dabrafenib)https://practicaldermatology.com/news/20140109-fda_approves_combination_use_of_gsks_mekinist_trametinib_and_tafinlar_dabrafenib/2459375/GlaxoSmithKline plc [LSE/NYSE: GSK] has received FDA approval of Mekinist® (trametinib) for use in combination with Tafinlar® (dabrafenib) for the treatment of patients with unresectable melanoma or metastatic melanoma with BRAF V600E or V600K mutation
- KYTHERA Biopharmaceuticals to Present at 32nd Annual J.P. Morgan Healthcare Conferencehttps://practicaldermatology.com/news/20140107-kythera_biopharmaceuticals_to_present_at_32nd_annual_jp_morgan_healthcare_conference/2459378/KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that Keith Leonard, president and chief executive officer, will present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
- Suneva Medical Announces 12-Month Safety Results From Artefill® Acne Scar Studyhttps://practicaldermatology.com/news/20140107-suneva_medical_announces_12-month_safety_results_from_artefill_acne_scar_study/2459379/Suneva Medical Inc. announced the 12-month follow-up data from its randomized, double-blinded, multi-center, Pivotal acne scar investigational study evaluating the safety and efficacy of ArteFillâ, a dermal filler, to treat acne scars.